Skip to content

Effect of blood thinning medicine in COVID-19 infection

Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients: A Pilot Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027503
Enrollment
60
Registered
2020-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Aspirin: Low dose aspirin (75 mg OD) for 10 days along with standard of care Control Intervention1: Standard of Care: Standard of care will included standard practice of the institute a

Sponsors

Dr Souvik Maitra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult (aged between 18 and 65y) patients with laboratory confirmed SARS- CoV-2 infection with hypoxemia (defined by room air SpO2 <= 94%) at the time of randomization will be included.

Exclusion criteria

Exclusion criteria: 1. Refusal to participate 2. Mechanically ventilated patients 3. Patients with P/F ratio 4. Patients with any known coagulation disorder 5. Patients with known platelet function disorder 6. Patients who are already on antiplatelet therapy 7. Patients with thrombocytopenia (platelet count 8. Patients with any previous intracranial pathology 9. Patients with known gastric/ duodenal ulcer 10. Patients with history of gastro-intestinal bleeding within 3 months 11. Pregnancy women or women who are breastfeeding their children 12. Known allergy to aspirin

Design outcomes

Primary

MeasureTime frame
To compare SpO2/ FiO2 ratio in day 1- 7 post randomization in both the groupsTimepoint: day 1- 7 post randomization

Secondary

MeasureTime frame
1. To compare the ventilation free days (VFD. 2. To compare the high flow nasal oxygen and/ or NIV free days (NVFD) in both the groups. 3. To compare supplemental oxygen free days (OFD). 4. To compare mortality in both the groups. Timepoint: 28 day post randomization;5. To compare duration of hospital stay in both the groups. 6. To compare incidence of new onset non- respiratory organ dysfunction (AKI) in both the groups. 7. To compare any adverse effects (major bleeding requiring transfusion, minor bleeding). 8. To compare the incidence of lower limb deep vein thrombosis in both the groups Timepoint: Till hospital discharge/ 28 day

Countries

India

Contacts

Public ContactDr Souvik Maitra

All India Institute of Medical Sciences, New Delhi

souvikmaitra@live.com08146727891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026